Caforio Giovanni's Form 4 filing
Bristol Myers Squibb CoBMY · filed Sep 16, 2022
- Accession no.
- 0000014272-22-000172
- Filed
- Sep 16, 2022
- Trade date
- Sep 15, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $3.59M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Caforio GiovanniCIK 0001533201 | Director, Officer (Board Chair and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2022 | Common Stock, $0.10 par value | SSaleDisposed | −50,000 | $71.84F1 | −$3,592,000 | 501,104.33 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $71.830 to $71.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.